A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study-Reference-Cited by-同舟云学术

A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

Published:2008-05 Issue:5 Volume:19 Page:977-983
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Burtness B.A.,Manola J.,Axelrod R.,Argiris A.,Forastiere A.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/5/977/401026/mdm591.pdf

Reference21 articles.

1. American Cancer SocietyCancer Facts and Figures 2007 http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf

2. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study;Forastiere;J Clin Oncol,1992

3. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393;Forastiere;J Clin Oncol,2001

4. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group;Gibson;J Clin Oncol,2005

5. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene;Hanania;Gene Ther,1995

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pan-cancer analysis and experimental validation reveal FAM72D as a potential novel biomarker and therapeutic target in lung adenocarcinoma;Gene;2024-11

2. Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer;Turkish Journal of Oncology;2021

3. Role of Systemic Therapy;Management of Oral Cancers;2020-09-09

4. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis;Critical Reviews in Oncology/Hematology;2020-09

5. Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio;2019-08-01